SMITH & NEPHEW PLC
17 November 2021
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM.
On 16 November 2021, Smith+Nephew was notified that the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") vested under the Smith & Nephew Global Share Plan 2010.
1. FINAL VESTING ON 13 NOVEMBER 2021 OF A CONDITIONAL SHARE AWARD MADE UNDER THE GLOBAL SHARE PLAN 2010:
The award was granted under the Global Share Plan 2010 on 13 November 2018. One third of the shares vested on 13 November 2019, a further third vested on 13 November 2020 and the final third vested on 13 November 2021. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards.
The following relates to individuals included in the below notification:
|
Reason for the notification |
|
|
Initial notification /Amendment |
Initial notification |
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
Name |
Smith & Nephew plc |
|
LEI |
213800ZTMDN8S67S1H61 |
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
Description of the financial instrument, type of instrument
|
Smith & Nephew plc ordinary shares of USD 0.20 each
|
|
Identification code |
ISIN: GB0009223206 |
|
Nature of the transaction |
Final vesting of a Conditional Share Award granted on 13 November 2018 under the Smith & Nephew Global Share Plan 2010. |
|
Date of Transaction |
2021 - 11 - 15 |
|
Place of Transaction |
London Stock Exchange (XLON) |
|
Name (Position) |
Director / PDMR |
Price |
Volume |
Aggregated information |
Total Ordinary Share Holding following the transaction * |
Total Ordinary Share Holding as a % of the Company's ISC following the transaction * |
|
Skip Kiil (President Orthopaedics) |
PDMR |
£13.105
|
18,351 (of which 7,247 were sold and 11,104 retained) |
N/A Single Transaction |
23,306.12693 ordinary shares |
0.00263%
|
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
2. SKIP KIIL - SALE OF ORDINARY SHARES
|
Reason for the notification |
|
|
Initial notification /Amendment |
Initial notification |
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
Name |
Smith & Nephew plc |
|
LEI |
213800ZTMDN8S67S1H61 |
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
Description of the financial instrument, type of instrument |
Smith & Nephew plc ordinary shares of USD 0.20 each |
|
Identification code |
ISIN: GB0009223206 |
|
Nature of the transaction |
Sale of ordinary shares. |
|
Date of Transaction |
2021 - 11 - 16 |
|
Place of Transaction |
London Stock Exchange (XLON) |
|
Name (Position) |
Director / PDMR |
Price (£) |
Volume |
Aggregated information |
Total Ordinary Share Holding following the transaction * |
Total Ordinary Share Holding as a % of the Company's ISC following the transaction * |
|
Skip Kiil (President Orthopaedics) |
PDMR |
13.124612 |
23,306 |
N/A Single Transaction |
0.12693 ordinary shares |
0.00000% |
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
Susan Swabey
Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477410
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
